Kovitz Investment Group Partners LLC Buys Shares of 19,201 SAB Biotherapeutics, Inc. (NASDAQ:SABS)

Kovitz Investment Group Partners LLC acquired a new stake in shares of SAB Biotherapeutics, Inc. (NASDAQ:SABS) during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm acquired 19,201 shares of the company’s stock, valued at approximately $52,000. Kovitz Investment Group Partners LLC owned approximately 0.21% of SAB Biotherapeutics as of its most recent filing with the Securities & Exchange Commission.

Wall Street Analysts Forecast Growth

Several research firms recently commented on SABS. Craig Hallum assumed coverage on shares of SAB Biotherapeutics in a research note on Wednesday, October 9th. They set a “buy” rating and a $11.00 price objective for the company. Oppenheimer reissued an “outperform” rating and issued a $12.00 price objective on shares of SAB Biotherapeutics in a research report on Thursday, September 12th. Finally, Chardan Capital reiterated a “buy” rating and issued a $25.00 price target on shares of SAB Biotherapeutics in a research note on Thursday, November 7th. Five analysts have rated the stock with a buy rating, According to data from MarketBeat, SAB Biotherapeutics has a consensus rating of “Buy” and a consensus price target of $12.40.

SAB Biotherapeutics Price Performance

Shares of SABS stock opened at $4.08 on Friday. The company has a debt-to-equity ratio of 0.09, a current ratio of 3.69 and a quick ratio of 3.69. SAB Biotherapeutics, Inc. has a fifty-two week low of $2.16 and a fifty-two week high of $8.40. The stock’s 50-day simple moving average is $3.17 and its 200-day simple moving average is $2.93.

SAB Biotherapeutics (NASDAQ:SABS) last announced its quarterly earnings data on Wednesday, November 6th. The company reported ($1.12) EPS for the quarter, missing the consensus estimate of ($1.07) by ($0.05). SAB Biotherapeutics had a negative net margin of 1,450.14% and a negative return on equity of 94.37%. On average, analysts forecast that SAB Biotherapeutics, Inc. will post -3.69 EPS for the current year.

About SAB Biotherapeutics

SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.